The antibody production market comprises products that are required during the different stages of bioprocessing of antibodies, such as upstream processing, downstream processing, and filtration. The global antibody production market is projected to reach USD 13.28 Billion by 2021 from USD 7.45 Billion in 2016, at a CAGR of 12.3% during the forecast period of 2016 to 2021.
The improved approval rate of therapeutic antibodies by regulatory authorities, patent expiry of blockbuster monoclonal antibodies, increasing adoption of targeted immunotherapy, and increased R&D expenditure of pharmaceutical and biotechnology companies are driving the overall antibody production market. The increasing prevalence of infectious diseases and rising demand for protein therapeutics are expected to provide growth opportunities for players operating in this market.
Download the PDF Brochure for More Details@ http://bit.ly/2CvtpNz
Restraints:
# Cost Constraints Related to the Adoption of Membrane Filters
Opportunities:
# Rising Demand for Protein Therapeutics
# Increasing Risk of Infectious Diseases
# Patent Expiry of Blockbuster Mabs
Challenges:
# High Costs of Primary Antibodies
In this report, the antibody production market is segmented on the basis of process, end user, and region. Based on process, the antibody production market is categorized into products for upstream processing, downstream processing, and filtration. The downstream processing segment is expected to account for the largest share of the antibody production market in 2016. This segment is also projected to register the highest CAGR during the forecast period.
On the basis of end user, the antibody production market is segmented into pharmaceutical and biotechnology companies, research institutes, and diagnostic laboratories. The pharmaceutical and biotechnology companies segment is expected to account for the largest share of the market in 2016, and is projected to register the highest CAGR during the forecast period.
Geographically, the global antibody production market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America, Middle East, and Africa). North America is expected to account for the largest share of the antibody production market in 2016, followed by Europe. The Asia-Pacific region offers significant growth opportunities for companies offering antibody production products, and is projected to grow at the highest CAGR during the forecast period.
Talk to Our Research Experts for more Detailed Information@ http://bit.ly/2Rbfb8F
Prominent players in the antibody production market include GE Healthcare (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), Pall Corporation (U.S.), Sigma-Aldrich Corporation (Germany), Eppendorf AG (Germany), Cellab GmbH (Germany), INTEGRA Biosciences AG (Switzerland), and FiberCell Systems Inc. (U.S.).
Target Audience:
- Equipment and consumable manufacturing companies
- Equipment and consumable suppliers and distributors
- Research institutes
- Venture capitalists
- Biotechnology and pharmaceutical companies
- Diagnostic laboratories
